|
|
News Breaks | | | | October 17, 2012 | | 08:05 EDT |  | PPHM | Peregrine: currently has 7 ongoing clinical trials for bavituximab
There are currently seven ongoing clinical trials for Peregrine's lead oncology product bavituximab, including two randomized Phase II clinical trials sponsored by Peregrine and five independent Investigator-Sponsored Trials, or ISTs. With this number of ongoing clinical trials, Peregrine is well positioned for constant clinical news flow for the remainder of 2012 and into 2013. Peregrine expects to have important median overall survival data from two of its randomized Phase II trials in front-line non-small cell lung cancer, or NSCLC, and pancreatic cancer towards year-end or early next calendar year. Both of these trials are open-label, Phase II clinical trials evaluating bavituximab plus chemotherapy versus chemotherapy alone. | |
|
News For PPHM From The Last 14 Days Check below for free stories on PPHM the last two weeks. |
|
|
| June 10, 2013 | | 12:28 EDT |  | PPHM | Peregrine management to meet with Roth Capital
 Subscribe for More Information | |
|
|
|
|
|
|
